Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 876,615Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Linzess

02 8Linzess/Constella

PharmaCompass

01

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 667

2019 Revenue in Millions : 0

Growth (%) : 100

Abbvie Company Banner

02

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 1,038

2020 Revenue in Millions : 667

Growth (%) : 56

Abbvie Company Banner

03

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 1,035

2021 Revenue in Millions : 1,038

Growth (%) : -0.3

Abbvie Company Banner

04

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2023 Revenue in Millions : 1,108

2022 Revenue in Millions : 1,035

Growth (%) : 7.1

Abbvie Company Banner

05

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2017 Revenue in Millions : 723

2016 Revenue in Millions : 643

Growth (%) : 12

Abbvie CB

06

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2018 Revenue in Millions : 785

2017 Revenue in Millions : 723

Growth (%) : 9%

Abbvie CB

07

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2016 Revenue in Millions : 643

2015 Revenue in Millions : 459

Growth (%) : 40

Abbvie CB

08

Brand Name : Linzess/Constella

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 827

2018 Revenue in Millions : 785

Growth (%) : 5

Abbvie CB

09

Brand Name : Linzess

Linaclotide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Linzess

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 57

2019 Revenue in Millions : 49

Growth (%) : 15

blank

10

Brand Name : Linzess

Linaclotide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Linzess

arrow
Antibody Engineering
Not Confirmed

Linaclotide

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 58

2020 Revenue in Millions : 56

Growth (%) : 11

blank